Featured Company News – Jazz Pharma to Partner with ImmunoGen for the Development and Commercialization of Antibody-Drug Conjugate Products

LONDON, UK / ACCESSWIRE / August 31, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) (“Jazz”), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=JAZZ. The Dublin based Company announced on August 29, 2017, that it has signed a collaboration and option agreement with ImmunoGen, Inc., (NASDAQ: IMGN) pursuant to which Jazz will receive exclusive, worldwide rights for the development and commercialization of two early-stage, hematology-related antibody-drug conjugate (ADC) programs. For immediate access to our complimentary reports, including today’s coverage, register for free now at:

http://protraderdaily.com/register/

At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on JAZZ and IMGN. Go directly to your stock of interest and access today’s free coverage at:

http://protraderdaily.com/optin/?symbol=JAZZ

http://protraderdaily.com/optin/?symbol=IMGN

The programs include IMGN779, a CD33-targeted ADC for the treatment of acute myeloid leukemia in Phase-1 testing, and IMGN632, a CD123-targeted ADC for hematological malignancies expected to enter clinical testing before the end of the year. The agreement also includes an additional program that will be assigned to Jazz during the term of the agreement.

Terms of the Agreement

Prior to opt-in by Jazz, ImmunoGen will undertake the responsibility of the development of the three ADC programs. Following any opt-in, Jazz would be liable for further development and for potential regulatory submissions and commercialization.

Jazz will pay ImmunoGen an upfront payment of $75 million. For supporting the ADC programs, Jazz will also pay ImmunoGen up to $100 million in development funding over seven years.

Jazz can also exercise its opt-in right at any time prior to a pivotal study or any time prior to a biologics license application (BLA), upon payment of an option exercise fee of mid-double digit millions or low triple digit millions, respectively.

For each program to which Jazz elects to opt-in, ImmunoGen would be eligible to receive milestone payments based on receiving regulatory approval of the applicable product, along with tiered royalties as a percentage of commercial sales by Jazz, which would depend upon sales levels and the stage of development at the time of opt-in.

Post opt-in, Jazz and ImmunoGen would share costs associated with developing and obtaining regulatory approvals of the applicable product in the United States and the European Union.

Collaboration Supports Jazz’s Long-Term Commitment of Expanding its Hematology/Oncology Portfolio

Bruce Cozadd, Jazz Pharma’s Chairman and CEO, expressed his happiness to enter into collaboration with ImmunoGen. This investment supports the Company’s long-term commitment to expand its hematology/oncology portfolio with the potential addition of multiple innovative antibody drug conjugates. Bruce added that Jazz is looking forward to the advancement of these ADC programs and the potential synergy of these compounds with its current products and pipeline, as new therapeutic options for cancer patients are urgently needed.

Partnership Advances ImmunoGen’s Goal of Accelerating Development of its Early-Stage Novel ADC Assets

Mark Enyedy, President and CEO of ImmunoGen, commented that this strategic partnership with Jazz significantly advances ImmunoGen’s goal of accelerating the development of its early-stage novel ADC assets. This deal joins the Company with a global partner, provides it with substantial funding to support these programs, and preserves the right to co-commercialize one of these assets. Mark believes that Jazz has demonstrated the ability to bring innovative compounds to patients and will make an ideal partner to help develop and commercialize ImmunoGen’s novel ADC assets targeting AML. He added that this partnership significantly strengthens the Company’s financial position as well.

About IMGN779

IMGN779 is a novel ADC that is a potential treatment for cancers that express CD33, including acute myeloid leukemia (AML). IMGN779 is designed to selectively target cancer cells that express CD33 and kill them via the DNA-acting payload agent DGN462. IMGN779 is in Phase-1 clinical testing for the treatment of AML.

About IMGN632

IMGN632 is a new CD123-targeting preclinical stage ADC that is a potential treatment for AML, myelodysplastic syndrome, B-cell acute lymphocytic leukemia, and other CD123-positive malignancies. IMGN632 utilizes novel payload, linker and antibody technology, and in preclinical models has demonstrated an impressive therapeutic window against CD123-positive malignancies.

Last Close Stock Review

At the closing bell, on Wednesday, August 30, 2017, Jazz Pharma’s stock marginally advanced 0.05%, ending the trading session at $145.94. A total volume of 424.80 thousand shares have exchanged hands. The Company’s stock price surged 7.17% in the past six months and 15.61% in the previous twelve months. Moreover, the stock soared 33.85% since the start of the year. The stock is trading at a PE ratio of 22.23 and currently has a market cap of $8.91 billion.

On Wednesday, August 30, 2017, the stock closed the trading session at $8.47, surging 11.74% from its previous closing price of $7.58. A total volume of 11.51 million shares have exchanged hands, which was higher than the 3-month average volume of 3.07 million shares. ImmunoGen’s stock price soared 77.57% in the last three months, 136.92% in the past six months, and 194.10% in the previous twelve months. Furthermore, since the start of the year, shares of the Company have skyrocketed 315.20%. At Wednesday’s closing price, the stock’s net capitalization stands at $792.62 million.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charter holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily

ReleaseID: 474293